# Question 49

**Type:** Aneuploidy Analysis

**Question:** Which cancer types have the highest aneuploidy scores and how does this correlate with mutation burden across TCGA Pan-Cancer studies?

**Answer:**

I'll help you explore aneuploidy scores and mutation burden across TCGA Pan-Cancer studies. Let me start by finding the appropriate pan-cancer study.



Calling `resolve_and_route` with args:
```json
{
  "targetPage": "study",
  "studyKeywords": [
    "TCGA",
    "pan",
    "cancer"
  ]
}
```



Result from `resolve_and_route`:
```json
{"success":true,"message":"Found 35 matching studies (showing top 5 with detailed metadata). Review the user's original query to determine if it clearly matches one study. If yes, use that study's metadata to call navigate_to_studyview. If ambiguous, ask the user to choose.","data":{"recommendedTool":"navigate_to_studyview","needsStudySelection":true,"totalCount":35,"resolvedStudyIds":["pancan_pcawg_2020","nsclc_tcga_broad_2016","brca_tcga_pan_can_atlas_2018","coadread_tcga_pan_can_atlas_2018","gbm_tcga_pan_can_atlas_2018","ov_tcga_pan_can_atlas_2018","luad_tcga_pan_can_atlas_2018","ucec_tcga_pan_can_atlas_2018","hnsc_tcga_pan_can_atlas_2018","lgg_tcga_pan_can_atlas_2018","kirc_tcga_pan_can_atlas_2018","thca_tcga_pan_can_atlas_2018","prad_tcga_pan_can_atlas_2018","lusc_tcga_pan_can_atlas_2018","skcm_tcga_pan_can_atlas_2018","stad_tcga_pan_can_atlas_2018","blca_tcga_pan_can_atlas_2018","lihc_tcga_pan_can_atlas_2018","cesc_tcga_pan_can_atlas_2018","kirp_tcga_pan_can_atlas_2018","sarc_tcga_pan_can_atlas_2018","laml_tcga_pan_can_atlas_2018","paad_tcga_gdc","paad_tcga_pan_can_atlas_2018","esca_tcga_pan_can_atlas_2018","pcpg_tcga_pan_can_atlas_2018","tgct_tcga_pan_can_atlas_2018","thym_tcga_pan_can_atlas_2018","acc_tcga_pan_can_atlas_2018","meso_tcga_pan_can_atlas_2018","uvm_tcga_pan_can_atlas_2018","kich_tcga_pan_can_atlas_2018","ucs_tcga_pan_can_atlas_2018","dlbc_tcga_pan_can_atlas_2018","chol_tcga_pan_can_atlas_2018"],"studiesWithMetadata":[{"studyId":"pancan_pcawg_2020","name":"Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)","sampleCount":2922,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=pancan_pcawg_2020","metadata":{"clinicalAttributeIds":["AGE","ALCOHOL","ALCOHOL_HISTORY_INTENSITY","ANCESTRY_PRIMARY","CANCER_TYPE","CANCER_TYPE_DETAILED","CELLULARITY","FIRST THERAPY_RESPONSE","FIRST_THERAPY","GRADE","HISTOLOGY","HISTOLOGY_ABBREVIATION","HISTOLOGY_TIER1","HISTOLOGY_TIER2","HISTOLOGY_TIER3","HISTOLOGY_TIER4","ICD_10","ICGC_SAMPLE_ID","MUTATION_COUNT","ONCOTREE_CODE","ORGAN_SYSTEM","OS_MONTHS","OS_STATUS","PLOIDY","PROJECT_CODE","PURITY","PURITY_CONFUGURATION","SAMPLE_CLASS","SAMPLE_COUNT","SAMPLE_TYPE","SEQUENCING_TYPE","SEX","STAGE","TBL_SCORE","TMB_NONSYNONYMOUS","TOBACCO_SMOKING_HISTORY_INDICATOR","TOBACCO_SMOKING_INTENSITY","TUMOR_SAMPLE_HISTOLOGY_CODE","WGD"],"molecularProfileIds":["pancan_pcawg_2020_cna","pancan_pcawg_2020_mirna","pancan_pcawg_2020_mirna_median_Zscores","pancan_pcawg_2020_mrna_seq_fpkm_capture","pancan_pcawg_2020_mrna_seq_fpkm_capture_all_sample_Zscores","pancan_pcawg_2020_mutational_signatures_contribution_DBS","pancan_pcawg_2020_mutational_signatures_contribution_ID","pancan_pcawg_2020_mutational_signatures_contribution_SBS","pancan_pcawg_2020_mutational_signatures_counts_DBS","pancan_pcawg_2020_mutational_signatures_counts_ID","pancan_pcawg_2020_mutational_signatures_counts_SBS","pancan_pcawg_2020_mutations"]}},{"studyId":"nsclc_tcga_broad_2016","name":"Pan-Lung Cancer (TCGA, Nat Genet 2016)","sampleCount":1144,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=nsclc_tcga_broad_2016","metadata":{"clinicalAttributeIds":["AGE","AGE_AT_SURGERY","CANCER_TYPE","CANCER_TYPE_DETAILED","DAYS_TO_DEATH","DAYS_TO_LAST_FOLLOWUP","FRACTION_GENOME_ALTERED","HISTORY_NEOADJUVANT_TRTYN","HISTORY_OTHER_MALIGNANCY","MUTATION_COUNT","M_STAGE","N_STAGE","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","SAMPLE_COUNT","SEX","SMOKING_HISTORY","SMOKING_PACK_YEARS","SOMATIC_STATUS","STAGE","TMB_NONSYNONYMOUS","T_STAGE"],"molecularProfileIds":["nsclc_tcga_broad_2016_cna","nsclc_tcga_broad_2016_mutations","nsclc_tcga_broad_2016_structural_variants"]}},{"studyId":"brca_tcga_pan_can_atlas_2018","name":"Breast Invasive Carcinoma (TCGA, PanCancer Atlas)","sampleCount":1084,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=brca_tcga_pan_can_atlas_2018","metadata":{"clinicalAttributeIds":["AGE","AJCC_PATHOLOGIC_TUMOR_STAGE","AJCC_STAGING_EDITION","ANEUPLOIDY_SCORE","BUFFA_HYPOXIA_SCORE","CANCER_TYPE","CANCER_TYPE_ACRONYM","CANCER_TYPE_DETAILED","DAYS_LAST_FOLLOWUP","DAYS_TO_BIRTH","DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS","DFS_MONTHS","DFS_STATUS","DSS_MONTHS","DSS_STATUS","ETHNICITY","FORM_COMPLETION_DATE","FRACTION_GENOME_ALTERED","GENETIC_ANCESTRY_LABEL","GRADE","HISTORY_NEOADJUVANT_TRTYN","ICD_10","ICD_O_3_HISTOLOGY","ICD_O_3_SITE","INFORMED_CONSENT_VERIFIED","IN_PANCANPATHWAYS_FREEZE","MSI_SCORE_MANTIS","MSI_SENSOR_SCORE","MUTATION_COUNT","NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","OTHER_PATIENT_ID","PATH_M_STAGE","PATH_N_STAGE","PATH_T_STAGE","PERSON_NEOPLASM_CANCER_STATUS","PFS_MONTHS","PFS_STATUS","PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT","PRIOR_DX","RACE","RADIATION_THERAPY","RAGNUM_HYPOXIA_SCORE","SAMPLE_COUNT","SAMPLE_TYPE","SEX","SOMATIC_STATUS","SUBTYPE","TBL_SCORE","TISSUE_PROSPECTIVE_COLLECTION_INDICATOR","TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR","TISSUE_SOURCE_SITE","TISSUE_SOURCE_SITE_CODE","TMB_NONSYNONYMOUS","TUMOR_TISSUE_SITE","TUMOR_TYPE","WEIGHT","WINTER_HYPOXIA_SCORE"],"molecularProfileIds":["brca_tcga_pan_can_atlas_2018_armlevel_cna","brca_tcga_pan_can_atlas_2018_genetic_ancestry","brca_tcga_pan_can_atlas_2018_gistic","brca_tcga_pan_can_atlas_2018_log2CNA","brca_tcga_pan_can_atlas_2018_methylation_hm27_hm450_merge","brca_tcga_pan_can_atlas_2018_mutations","brca_tcga_pan_can_atlas_2018_phosphoprotein_quantification","brca_tcga_pan_can_atlas_2018_protein_quantification","brca_tcga_pan_can_atlas_2018_protein_quantification_zscores","brca_tcga_pan_can_atlas_2018_rna_seq_v2_mrna","brca_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_Zscores","brca_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_Zscores","brca_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_ref_normal_Zscores","brca_tcga_pan_can_atlas_2018_rppa","brca_tcga_pan_can_atlas_2018_rppa_Zscores","brca_tcga_pan_can_atlas_2018_structural_variants"]}},{"studyId":"coadread_tcga_pan_can_atlas_2018","name":"Colorectal Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":594,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=coadread_tcga_pan_can_atlas_2018","metadata":{"clinicalAttributeIds":["AGE","AJCC_PATHOLOGIC_TUMOR_STAGE","AJCC_STAGING_EDITION","ANEUPLOIDY_SCORE","BUFFA_HYPOXIA_SCORE","CANCER_TYPE","CANCER_TYPE_ACRONYM","CANCER_TYPE_DETAILED","DAYS_LAST_FOLLOWUP","DAYS_TO_BIRTH","DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS","DFS_MONTHS","DFS_STATUS","DSS_MONTHS","DSS_STATUS","ETHNICITY","FORM_COMPLETION_DATE","FRACTION_GENOME_ALTERED","GENETIC_ANCESTRY_LABEL","GRADE","HISTORY_NEOADJUVANT_TRTYN","ICD_10","ICD_O_3_HISTOLOGY","ICD_O_3_SITE","INFORMED_CONSENT_VERIFIED","IN_PANCANPATHWAYS_FREEZE","MSI_SCORE_MANTIS","MSI_SENSOR_SCORE","MUTATION_COUNT","NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","OTHER_PATIENT_ID","PATH_M_STAGE","PATH_N_STAGE","PATH_T_STAGE","PERSON_NEOPLASM_CANCER_STATUS","PFS_MONTHS","PFS_STATUS","PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT","PRIOR_DX","RACE","RADIATION_THERAPY","RAGNUM_HYPOXIA_SCORE","SAMPLE_COUNT","SAMPLE_TYPE","SEX","SOMATIC_STATUS","SUBTYPE","TBL_SCORE","TISSUE_PROSPECTIVE_COLLECTION_INDICATOR","TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR","TISSUE_SOURCE_SITE","TISSUE_SOURCE_SITE_CODE","TMB_NONSYNONYMOUS","TUMOR_TISSUE_SITE","TUMOR_TYPE","WEIGHT","WINTER_HYPOXIA_SCORE"],"molecularProfileIds":["coadread_tcga_pan_can_atlas_2018_armlevel_cna","coadread_tcga_pan_can_atlas_2018_genetic_ancestry","coadread_tcga_pan_can_atlas_2018_gistic","coadread_tcga_pan_can_atlas_2018_log2CNA","coadread_tcga_pan_can_atlas_2018_methylation_hm27_hm450_merge","coadread_tcga_pan_can_atlas_2018_mutations","coadread_tcga_pan_can_atlas_2018_protein_quantification","coadread_tcga_pan_can_atlas_2018_protein_quantification_zscores","coadread_tcga_pan_can_atlas_2018_rna_seq_v2_mrna","coadread_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_Zscores","coadread_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_Zscores","coadread_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_ref_normal_Zscores","coadread_tcga_pan_can_atlas_2018_rppa","coadread_tcga_pan_can_atlas_2018_rppa_Zscores","coadread_tcga_pan_can_atlas_2018_structural_variants"]}},{"studyId":"gbm_tcga_pan_can_atlas_2018","name":"Glioblastoma Multiforme (TCGA, PanCancer Atlas)","sampleCount":592,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=gbm_tcga_pan_can_atlas_2018","metadata":{"clinicalAttributeIds":["AGE","AJCC_PATHOLOGIC_TUMOR_STAGE","AJCC_STAGING_EDITION","ANEUPLOIDY_SCORE","BUFFA_HYPOXIA_SCORE","CANCER_TYPE","CANCER_TYPE_ACRONYM","CANCER_TYPE_DETAILED","DAYS_LAST_FOLLOWUP","DAYS_TO_BIRTH","DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS","DFS_MONTHS","DFS_STATUS","DSS_MONTHS","DSS_STATUS","ETHNICITY","FORM_COMPLETION_DATE","FRACTION_GENOME_ALTERED","GENETIC_ANCESTRY_LABEL","GRADE","HISTORY_NEOADJUVANT_TRTYN","ICD_10","ICD_O_3_HISTOLOGY","ICD_O_3_SITE","INFORMED_CONSENT_VERIFIED","IN_PANCANPATHWAYS_FREEZE","MSI_SCORE_MANTIS","MSI_SENSOR_SCORE","MUTATION_COUNT","NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","OTHER_PATIENT_ID","PATH_M_STAGE","PATH_N_STAGE","PATH_T_STAGE","PERSON_NEOPLASM_CANCER_STATUS","PFS_MONTHS","PFS_STATUS","PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT","PRIOR_DX","RACE","RADIATION_THERAPY","RAGNUM_HYPOXIA_SCORE","SAMPLE_COUNT","SAMPLE_TYPE","SEX","SOMATIC_STATUS","SUBTYPE","TBL_SCORE","TISSUE_PROSPECTIVE_COLLECTION_INDICATOR","TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR","TISSUE_SOURCE_SITE","TISSUE_SOURCE_SITE_CODE","TMB_NONSYNONYMOUS","TUMOR_TISSUE_SITE","TUMOR_TYPE","WEIGHT","WINTER_HYPOXIA_SCORE"],"molecularProfileIds":["gbm_tcga_pan_can_atlas_2018_armlevel_cna","gbm_tcga_pan_can_atlas_2018_genetic_ancestry","gbm_tcga_pan_can_atlas_2018_gistic","gbm_tcga_pan_can_atlas_2018_log2CNA","gbm_tcga_pan_can_atlas_2018_methylation_hm27_hm450_merge","gbm_tcga_pan_can_atlas_2018_mutations","gbm_tcga_pan_can_atlas_2018_rna_seq_v2_mrna","gbm_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_Zscores","gbm_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_Zscores","gbm_tcga_pan_can_atlas_2018_rppa","gbm_tcga_pan_can_atlas_2018_rppa_Zscores","gbm_tcga_pan_can_atlas_2018_structural_variants"]}}],"otherStudies":[{"studyId":"ov_tcga_pan_can_atlas_2018","name":"Ovarian Serous Cystadenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":585,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=ov_tcga_pan_can_atlas_2018"},{"studyId":"luad_tcga_pan_can_atlas_2018","name":"Lung Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":566,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=luad_tcga_pan_can_atlas_2018"},{"studyId":"ucec_tcga_pan_can_atlas_2018","name":"Uterine Corpus Endometrial Carcinoma (TCGA, PanCancer Atlas)","sampleCount":529,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=ucec_tcga_pan_can_atlas_2018"},{"studyId":"hnsc_tcga_pan_can_atlas_2018","name":"Head and Neck Squamous Cell Carcinoma (TCGA, PanCancer Atlas)","sampleCount":523,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=hnsc_tcga_pan_can_atlas_2018"},{"studyId":"lgg_tcga_pan_can_atlas_2018","name":"Brain Lower Grade Glioma (TCGA, PanCancer Atlas)","sampleCount":514,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=lgg_tcga_pan_can_atlas_2018"},{"studyId":"kirc_tcga_pan_can_atlas_2018","name":"Kidney Renal Clear Cell Carcinoma (TCGA, PanCancer Atlas)","sampleCount":512,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=kirc_tcga_pan_can_atlas_2018"},{"studyId":"thca_tcga_pan_can_atlas_2018","name":"Thyroid Carcinoma (TCGA, PanCancer Atlas)","sampleCount":500,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=thca_tcga_pan_can_atlas_2018"},{"studyId":"prad_tcga_pan_can_atlas_2018","name":"Prostate Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":494,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=prad_tcga_pan_can_atlas_2018"},{"studyId":"lusc_tcga_pan_can_atlas_2018","name":"Lung Squamous Cell Carcinoma (TCGA, PanCancer Atlas)","sampleCount":487,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=lusc_tcga_pan_can_atlas_2018"},{"studyId":"skcm_tcga_pan_can_atlas_2018","name":"Skin Cutaneous Melanoma (TCGA, PanCancer Atlas)","sampleCount":448,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=skcm_tcga_pan_can_atlas_2018"},{"studyId":"stad_tcga_pan_can_atlas_2018","name":"Stomach Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":440,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=stad_tcga_pan_can_atlas_2018"},{"studyId":"blca_tcga_pan_can_atlas_2018","name":"Bladder Urothelial Carcinoma (TCGA, PanCancer Atlas)","sampleCount":411,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=blca_tcga_pan_can_atlas_2018"},{"studyId":"lihc_tcga_pan_can_atlas_2018","name":"Liver Hepatocellular Carcinoma (TCGA, PanCancer Atlas)","sampleCount":372,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=lihc_tcga_pan_can_atlas_2018"},{"studyId":"cesc_tcga_pan_can_atlas_2018","name":"Cervical Squamous Cell Carcinoma (TCGA, PanCancer Atlas)","sampleCount":297,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=cesc_tcga_pan_can_atlas_2018"},{"studyId":"kirp_tcga_pan_can_atlas_2018","name":"Kidney Renal Papillary Cell Carcinoma (TCGA, PanCancer Atlas)","sampleCount":283,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=kirp_tcga_pan_can_atlas_2018"},{"studyId":"sarc_tcga_pan_can_atlas_2018","name":"Sarcoma (TCGA, PanCancer Atlas)","sampleCount":255,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=sarc_tcga_pan_can_atlas_2018"},{"studyId":"laml_tcga_pan_can_atlas_2018","name":"Acute Myeloid Leukemia (TCGA, PanCancer Atlas)","sampleCount":200,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=laml_tcga_pan_can_atlas_2018"},{"studyId":"paad_tcga_gdc","name":"Pancreatic Adenocarcinoma (TCGA, GDC)","sampleCount":186,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=paad_tcga_gdc"},{"studyId":"paad_tcga_pan_can_atlas_2018","name":"Pancreatic Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":184,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=paad_tcga_pan_can_atlas_2018"},{"studyId":"esca_tcga_pan_can_atlas_2018","name":"Esophageal Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":182,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=esca_tcga_pan_can_atlas_2018"},{"studyId":"pcpg_tcga_pan_can_atlas_2018","name":"Pheochromocytoma and Paraganglioma (TCGA, PanCancer Atlas)","sampleCount":178,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=pcpg_tcga_pan_can_atlas_2018"},{"studyId":"tgct_tcga_pan_can_atlas_2018","name":"Testicular Germ Cell Tumors (TCGA, PanCancer Atlas)","sampleCount":149,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=tgct_tcga_pan_can_atlas_2018"},{"studyId":"thym_tcga_pan_can_atlas_2018","name":"Thymoma (TCGA, PanCancer Atlas)","sampleCount":123,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=thym_tcga_pan_can_atlas_2018"},{"studyId":"acc_tcga_pan_can_atlas_2018","name":"Adrenocortical Carcinoma (TCGA, PanCancer Atlas)","sampleCount":92,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=acc_tcga_pan_can_atlas_2018"},{"studyId":"meso_tcga_pan_can_atlas_2018","name":"Mesothelioma (TCGA, PanCancer Atlas)","sampleCount":87,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=meso_tcga_pan_can_atlas_2018"},{"studyId":"uvm_tcga_pan_can_atlas_2018","name":"Uveal Melanoma (TCGA, PanCancer Atlas)","sampleCount":80,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=uvm_tcga_pan_can_atlas_2018"},{"studyId":"kich_tcga_pan_can_atlas_2018","name":"Kidney Chromophobe (TCGA, PanCancer Atlas)","sampleCount":65,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=kich_tcga_pan_can_atlas_2018"},{"studyId":"ucs_tcga_pan_can_atlas_2018","name":"Uterine Carcinosarcoma (TCGA, PanCancer Atlas)","sampleCount":57,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=ucs_tcga_pan_can_atlas_2018"},{"studyId":"dlbc_tcga_pan_can_atlas_2018","name":"Diffuse Large B-Cell Lymphoma (TCGA, PanCancer Atlas)","sampleCount":48,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=dlbc_tcga_pan_can_atlas_2018"},{"studyId":"chol_tcga_pan_can_atlas_2018","name":"Cholangiocarcinoma (TCGA, PanCancer Atlas)","sampleCount":36,"studyViewUrl":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study?id=chol_tcga_pan_can_atlas_2018"}]}}
```


Perfect! I can see that the TCGA PanCancer Atlas 2018 studies include **ANEUPLOIDY_SCORE** as a clinical attribute. This is exactly what you need. I notice there are individual cancer type studies from the PanCancer Atlas (e.g., brca_tcga_pan_can_atlas_2018, coadread_tcga_pan_can_atlas_2018, etc.), each with aneuploidy scores.

To answer your question about which cancer types have the highest aneuploidy scores and how this correlates with mutation burden (TMB_NONSYNONYMOUS), you'll want to explore these studies. Let me provide you with the best approach:

## Recommended Approach:

**For a comprehensive pan-cancer view**, I recommend using the **Plots tab** in StudyView to create scatter plots comparing aneuploidy scores vs. mutation burden across multiple cancer types. You can do this by:

1. **Querying multiple TCGA PanCancer Atlas studies together** - This allows cross-cancer comparison
2. **Using the Plots tab** to visualize ANEUPLOIDY_SCORE (Y-axis) vs TMB_NONSYNONYMOUS or MUTATION_COUNT (X-axis)
3. **Coloring by CANCER_TYPE** to see which cancer types cluster where

Let me generate a URL for you to explore several major cancer types together:



Calling `navigate_to_studyview_page` with args:
```json
{
  "studyIds": [
    "brca_tcga_pan_can_atlas_2018",
    "coadread_tcga_pan_can_atlas_2018",
    "gbm_tcga_pan_can_atlas_2018",
    "ov_tcga_pan_can_atlas_2018",
    "luad_tcga_pan_can_atlas_2018",
    "ucec_tcga_pan_can_atlas_2018",
    "hnsc_tcga_pan_can_atlas_2018",
    "lgg_tcga_pan_can_atlas_2018",
    "kirc_tcga_pan_can_atlas_2018",
    "thca_tcga_pan_can_atlas_2018",
    "prad_tcga_pan_can_atlas_2018",
    "lusc_tcga_pan_can_atlas_2018",
    "skcm_tcga_pan_can_atlas_2018",
    "stad_tcga_pan_can_atlas_2018",
    "blca_tcga_pan_can_atlas_2018",
    "lihc_tcga_pan_can_atlas_2018"
  ],
  "tab": "plots",
  "plotsHorzSelection": {
    "dataType": "clinical_attribute",
    "selectedDataSourceOption": "TMB_NONSYNONYMOUS"
  },
  "plotsVertSelection": {
    "dataType": "clinical_attribute",
    "selectedDataSourceOption": "ANEUPLOIDY_SCORE"
  },
  "plotsColoringSelection": {
    "selectedOption": "CANCER_TYPE"
  }
}
```



Result from `navigate_to_studyview_page`:
```json
{"success":true,"message":"Navigating to https://deploy-preview-5312--cbioportalfrontend.netlify.app/study/plots?id=brca_tcga_pan_can_atlas_2018%2Ccoadread_tcga_pan_can_atlas_2018%2Cgbm_tcga_pan_can_atlas_2018%2Cov_tcga_pan_can_atlas_2018%2Cluad_tcga_pan_can_atlas_2018%2Cucec_tcga_pan_can_atlas_2018%2Chnsc_tcga_pan_can_atlas_2018%2Clgg_tcga_pan_can_atlas_2018%2Ckirc_tcga_pan_can_atlas_2018%2Cthca_tcga_pan_can_atlas_2018%2Cprad_tcga_pan_can_atlas_2018%2Clusc_tcga_pan_can_atlas_2018%2Cskcm_tcga_pan_can_atlas_2018%2Cstad_tcga_pan_can_atlas_2018%2Cblca_tcga_pan_can_atlas_2018%2Clihc_tcga_pan_can_atlas_2018&plots_horz_selection=%7B%22dataType%22%3A%22clinical_attribute%22%2C%22selectedDataSourceOption%22%3A%22TMB_NONSYNONYMOUS%22%7D&plots_vert_selection=%7B%22dataType%22%3A%22clinical_attribute%22%2C%22selectedDataSourceOption%22%3A%22ANEUPLOIDY_SCORE%22%7D&plots_coloring_selection=%7B%22selectedOption%22%3A%22CANCER_TYPE%22%7D","url":"https://deploy-preview-5312--cbioportalfrontend.netlify.app/study/plots?id=brca_tcga_pan_can_atlas_2018%2Ccoadread_tcga_pan_can_atlas_2018%2Cgbm_tcga_pan_can_atlas_2018%2Cov_tcga_pan_can_atlas_2018%2Cluad_tcga_pan_can_atlas_2018%2Cucec_tcga_pan_can_atlas_2018%2Chnsc_tcga_pan_can_atlas_2018%2Clgg_tcga_pan_can_atlas_2018%2Ckirc_tcga_pan_can_atlas_2018%2Cthca_tcga_pan_can_atlas_2018%2Cprad_tcga_pan_can_atlas_2018%2Clusc_tcga_pan_can_atlas_2018%2Cskcm_tcga_pan_can_atlas_2018%2Cstad_tcga_pan_can_atlas_2018%2Cblca_tcga_pan_can_atlas_2018%2Clihc_tcga_pan_can_atlas_2018&plots_horz_selection=%7B%22dataType%22%3A%22clinical_attribute%22%2C%22selectedDataSourceOption%22%3A%22TMB_NONSYNONYMOUS%22%7D&plots_vert_selection=%7B%22dataType%22%3A%22clinical_attribute%22%2C%22selectedDataSourceOption%22%3A%22ANEUPLOIDY_SCORE%22%7D&plots_coloring_selection=%7B%22selectedOption%22%3A%22CANCER_TYPE%22%7D","data":{"studyIds":["brca_tcga_pan_can_atlas_2018","coadread_tcga_pan_can_atlas_2018","gbm_tcga_pan_can_atlas_2018","ov_tcga_pan_can_atlas_2018","luad_tcga_pan_can_atlas_2018","ucec_tcga_pan_can_atlas_2018","hnsc_tcga_pan_can_atlas_2018","lgg_tcga_pan_can_atlas_2018","kirc_tcga_pan_can_atlas_2018","thca_tcga_pan_can_atlas_2018","prad_tcga_pan_can_atlas_2018","lusc_tcga_pan_can_atlas_2018","skcm_tcga_pan_can_atlas_2018","stad_tcga_pan_can_atlas_2018","blca_tcga_pan_can_atlas_2018","lihc_tcga_pan_can_atlas_2018"],"studies":[{"studyId":"brca_tcga_pan_can_atlas_2018","name":"Breast Invasive Carcinoma (TCGA, PanCancer Atlas)","sampleCount":1084},{"studyId":"coadread_tcga_pan_can_atlas_2018","name":"Colorectal Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":594},{"studyId":"gbm_tcga_pan_can_atlas_2018","name":"Glioblastoma Multiforme (TCGA, PanCancer Atlas)","sampleCount":592},{"studyId":"ov_tcga_pan_can_atlas_2018","name":"Ovarian Serous Cystadenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":585},{"studyId":"luad_tcga_pan_can_atlas_2018","name":"Lung Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":566},{"studyId":"ucec_tcga_pan_can_atlas_2018","name":"Uterine Corpus Endometrial Carcinoma (TCGA, PanCancer Atlas)","sampleCount":529},{"studyId":"hnsc_tcga_pan_can_atlas_2018","name":"Head and Neck Squamous Cell Carcinoma (TCGA, PanCancer Atlas)","sampleCount":523},{"studyId":"lgg_tcga_pan_can_atlas_2018","name":"Brain Lower Grade Glioma (TCGA, PanCancer Atlas)","sampleCount":514},{"studyId":"kirc_tcga_pan_can_atlas_2018","name":"Kidney Renal Clear Cell Carcinoma (TCGA, PanCancer Atlas)","sampleCount":512},{"studyId":"thca_tcga_pan_can_atlas_2018","name":"Thyroid Carcinoma (TCGA, PanCancer Atlas)","sampleCount":500},{"studyId":"prad_tcga_pan_can_atlas_2018","name":"Prostate Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":494},{"studyId":"lusc_tcga_pan_can_atlas_2018","name":"Lung Squamous Cell Carcinoma (TCGA, PanCancer Atlas)","sampleCount":487},{"studyId":"skcm_tcga_pan_can_atlas_2018","name":"Skin Cutaneous Melanoma (TCGA, PanCancer Atlas)","sampleCount":448},{"studyId":"stad_tcga_pan_can_atlas_2018","name":"Stomach Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":440},{"studyId":"blca_tcga_pan_can_atlas_2018","name":"Bladder Urothelial Carcinoma (TCGA, PanCancer Atlas)","sampleCount":411},{"studyId":"lihc_tcga_pan_can_atlas_2018","name":"Liver Hepatocellular Carcinoma (TCGA, PanCancer Atlas)","sampleCount":372}],"tab":"plots","hasFilters":false,"hasPlotsConfig":true}}
```


Perfect! Here's your direct link to explore aneuploidy scores vs. mutation burden across 16 major TCGA PanCancer Atlas studies:

## ðŸ”— **Pan-Cancer Aneuploidy vs. Mutation Burden Analysis**

**https://deploy-preview-5312--cbioportalfrontend.netlify.app/study/plots?id=brca_tcga_pan_can_atlas_2018%2Ccoadread_tcga_pan_can_atlas_2018%2Cgbm_tcga_pan_can_atlas_2018%2Cov_tcga_pan_can_atlas_2018%2Cluad_tcga_pan_can_atlas_2018%2Cucec_tcga_pan_can_atlas_2018%2Chnsc_tcga_pan_can_atlas_2018%2Clgg_tcga_pan_can_atlas_2018%2Ckirc_tcga_pan_can_atlas_2018%2Cthca_tcga_pan_can_atlas_2018%2Cprad_tcga_pan_can_atlas_2018%2Clusc_tcga_pan_can_atlas_2018%2Cskcm_tcga_pan_can_atlas_2018%2Cstad_tcga_pan_can_atlas_2018%2Cblca_tcga_pan_can_atlas_2018%2Clihc_tcga_pan_can_atlas_2018&plots_horz_selection=%7B%22dataType%22%3A%22clinical_attribute%22%2C%22selectedDataSourceOption%22%3A%22TMB_NONSYNONYMOUS%22%7D&plots_vert_selection=%7B%22dataType%22%3A%22clinical_attribute%22%2C%22selectedDataSourceOption%22%3A%22ANEUPLOIDY_SCORE%22%7D&plots_coloring_selection=%7B%22selectedOption%22%3A%22CANCER_TYPE%22%7D**

---

## What This Shows:

This scatter plot displays:
- **X-axis:** TMB_NONSYNONYMOUS (Tumor Mutation Burden - nonsynonymous mutations)
- **Y-axis:** ANEUPLOIDY_SCORE (chromosomal instability measure)
- **Color:** Each cancer type is color-coded for easy identification
- **Total samples:** ~7,000+ samples across 16 cancer types

---

## Cancer Types Included:

1. **Breast Invasive Carcinoma** (1,084 samples)
2. **Colorectal Adenocarcinoma** (594 samples)
3. **Glioblastoma Multiforme** (592 samples)
4. **Ovarian Serous Cystadenocarcinoma** (585 samples)
5. **Lung Adenocarcinoma** (566 samples)
6. **Uterine Corpus Endometrial Carcinoma** (529 samples)
7. **Head and Neck Squamous Cell Carcinoma** (523 samples)
8. **Brain Lower Grade Glioma** (514 samples)
9. **Kidney Renal Clear Cell Carcinoma** (512 samples)
10. **Thyroid Carcinoma** (500 samples)
11. **Prostate Adenocarcinoma** (494 samples)
12. **Lung Squamous Cell Carcinoma** (487 samples)
13. **Skin Cutaneous Melanoma** (448 samples)
14. **Stomach Adenocarcinoma** (440 samples)
15. **Bladder Urothelial Carcinoma** (411 samples)
16. **Liver Hepatocellular Carcinoma** (372 samples)

---

## Expected Patterns (Based on Literature):

**High Aneuploidy Cancer Types:**
- Ovarian serous carcinoma
- Breast cancer (especially ER+ subtypes)
- Colorectal cancer (chromosomally unstable subtype)
- Gastric/stomach adenocarcinoma

**High TMB Cancer Types:**
- Skin cut

---

## Model Information
- **model**: us.anthropic.claude-sonnet-4-5-20250929-v1:0
- **temperature**: 0.0
- **max_output_tokens**: 1024
- **thinking_enabled**: False
- **thinking_budget_tokens**: 1024
- **response_time_seconds**: 28.676698158029467
- **agent_type**: mcp-navigator-agent

### Usage
- **input_tokens**: 80951
- **output_tokens**: 1935
- **total_tokens**: 82886
- **cache_creation_input_tokens**: 0
- **cache_read_input_tokens**: 0

---

*Generated on 2026-02-05 01:49:22*